Analytical Data
-
Gene name
STEAP2
- Application
-
Alternative Names
Prostate cancer-associated protein 1 Protein up-regulated in metastatic prostate cancer
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8NFT2
-
Expression Region
1-490aa
-
Molecular Weight
74.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Related Products
Protein Description
STEAP2 (Six-Transmembrane Epithelial Antigen of the Prostate 2) is a type of transmembrane protein primarily expressed in human prostate tissue, which has garnered significant interest in cancer research, particularly prostate cancer. The role of STEAP2 in tumor biology is intriguing due to its involvement in cell proliferation, survival, and the immune response. Research indicates that STEAP2 may function as a biomarker for cancer, providing insights into disease progression and potential therapeutic targets. The recombinant expression of STEAP2 facilitates detailed studies of its structure and function, enabling researchers to investigate its interactions with other cellular molecules and its role in signaling pathways. Moreover, recombinant STEAP2 is essential for developing targeted therapies and vaccines against prostate cancer, as it can be utilized in immunotherapeutic approaches. By elucidating the mechanisms underlying STEAP2’s action, researchers aim to improve diagnostic and treatment strategies, transforming the clinical management of prostate cancer and possibly other malignancies. The ongoing studies on STEAP2 highlight its promise as a valuable target in cancer research and therapy, underscoring the need for further exploration into its biological significance and therapeutic potential.
